Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
With a market cap of 33.22B, Insmed Incorporated(INSM) trades at $155.75. The stock has a price-to-earnings ratio of -25.29.
During the trading session on 2026-01-22, Insmed Incorporated(INSM) shares reached a daily high of $157.64 and a low of $153.19. At a current price of $155.75, the stock is +1.7% higher than the low and still -1.2% under the high.
Trading volume for Insmed Incorporated(INSM) stock has reached 918.08K, versus its average volume of 3.23M.
The stock's 52-week range extends from a low of $60.40 to a high of $212.75.
The stock's 52-week range extends from a low of $60.40 to a high of $212.75.
INSM News
In January 2026, Insmed reported strong preliminary 2025 results, with total revenue rising to US$606.4 million from US$363.7 million a year earlier, fueled by...
RBC Capital analyst Leonid Timashev raised the firm’s price target on Insmed (INSM) to $200 from $197 and keeps an Outperform rating on the shares. The firm upd...
Advertisement Why Insmed’s latest update matters for shareholders Insmed (INSM) recently issued preliminary 2025 figures and fresh guidance, highlighting reve...